Pfizer to maintain push to break into obesity market after setback

Analysts have forecast the overall obesity drug market could reach $100 billion by the end of the decade

Pfizer CEO Albert Bourla said it was unlikely the company would buy an obesity treatment in later stage development.

Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high-profile weight-loss drug candidate late last year due to strong side-effects, Chief Executive Albert Bourla said.

"Pfizer's position is that we believe that obesity is a place that we have the ability to play and win. So we will have to play," Bourla told reporters ahead of his presentation at the JP Morgan healthcare conference in San Francisco.